Dr Reddy’s Laboratories, on May 6th, announced the launched of its generic version of AndroGel testosterone in the US. AndroGel is used in treating adult males with no or low testosterone, caused due to some medical conditions.
The company’s testosterone gel 1.62 percent is a therapeutic-equivalent generic version of AndroGel 1.62 percent, developed by AbbVie Inc. It was sanctioned by the FDA, Dr Reddy’s said in a regulatory filing.
Citing IQVIA Health statistics for the year ending February 2019, the company said that the AndroGel brand and generic versions registered a revenue of around $815.6 million in the US. Currently, the shares of Dr Reddy’s Laboratories on the Bombay Stock Exchange are dealing at Rs 2,908.20, up 0.15%.